‹ ›
MYP_058043
← PREVIOUS NEXT → BACK
Basic Information
T-2635
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
38 amino acids
C193H305N57O62
Standard
Sequence
TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL
Physicochemical Analysis
4415.83 Da
4.64
-3.58
-3.79
-0.0943
-0.67
0.62
-0.15
46.93
87.89
0.0789
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1976.67
-17.65
69.0
59.0
149.0
312.0
5.0
41.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0105525 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV 098-T651 | CEM4 cells
0.004756 μM
IC50
Mammalian: 7.2 h; Yeast: >20 h; E. coli: >10 h
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. | Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. | Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. | DOI:10.1073/pnas.0701478104 | PMID:17640899 PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0123990 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV fusion inhibitor
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1
Monkey serum: Half-life is 16.3 h
PaperDwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. PMID:17640899 https://pubmed.ncbi.nlm.nih.gov/17640899/ PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0131648 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Fusion inhibitor
Qualitative inhibition
PaperHighly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors PatentUS7919101
RECORD: Rec_0133105 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral
098-T651 virus virus
0.021 μg/mL
IC50
Male cynomolgus monkey blood plasma (Intravenous), in vivo; 58680 s
PaperDesign of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
RECORD: Rec_0141813 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 098-T651
PMID17640899 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17640899/
FIRST PREV 1 2 3 4 5 NEXT LAST
Showing 5 records on this page · Page 2 of 5